BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 10779205)

  • 1. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
    Bastos da Silva M; Delaunois A; Gustin P; Godeau JM; Lekeux P
    Vet Res; 2000; 31(2):267-72. PubMed ID: 10779205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
    Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
    Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
    da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
    Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
    Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
    J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L; Floch A; Mondot S; Cavero I
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
    Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
    Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-bulnesene, a novel PAF receptor antagonist isolated from Pogostemon cablin.
    Hsu HC; Yang WC; Tsai WJ; Chen CC; Huang HY; Tsai YC
    Biochem Biophys Res Commun; 2006 Jul; 345(3):1033-8. PubMed ID: 16712790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor.
    Bennett SA; Birnboim HC
    Mol Carcinog; 1997 Dec; 20(4):366-75. PubMed ID: 9433481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antagonistic effect of hydroxysafflor yellow A on the platelet activating factor receptor].
    Zang BX; Jin M; Si N; Zhang Y; Wu W; Piao YZ
    Yao Xue Xue Bao; 2002 Sep; 37(9):696-9. PubMed ID: 12567893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
    Herbert JM; Laplace MC; Cailleau C; Maffrand JP
    J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages.
    Chen J; Giri SN
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1047-58. PubMed ID: 9190835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.